丙丁酚治疗非增殖性糖尿病视网膜病变的临床观察  

Clinical Observation of Probucol for Nonproliferative Diabetic Retinopathy

作　　者：蒋苏平[1] 陈忠平 

机构地区：[1]柳州市工人医院,柳州

出　　处：《眼科学》2014年第2期13-18,共6页Hans Journal of Ophthalmology

摘　　要：目的:观察丙丁酚治疗非增殖性糖尿病视网膜病变(NPDR)的临床疗效。方法:于2012年1月至2013年8月选取非增殖性糖尿病视网膜病变患者68例作为研究对象,再将非增殖性糖尿病视网膜病变(NPDR)患者分为四组:即:A组、强化治疗+丙丁酚组,共17例;B组、强化治疗组,共17例;C组、常规治疗 + 丙丁酚组,共17例;D组、常规治疗组,共17例,避免服用其它抗氧化剂。A、C组DR患者予丙丁酚0.375 g,每日2次。平均随访11.58 ±0.17个月。并比较观察4组干预前、1年后的视力、眼底及血脂(TC、LDLC)变化。结果:最终随访发现:1、A、C组NPDR患者的眼底情况较干预前显著改善(P 0.05);B、D组患者的眼底情况均无显著改善(P >0.05)。2、A、C组患者最佳矫正视力均较干预前显著提高(P 0.05);B、D组患者最佳矫正视力均无显著提高(P >0.05)。3、A、C组患者TC、LDLC水平均显著低于干预前(P 0.05);且干预后A、C组间TC、LDLC水平无显著性差异(P >0.05)。结论 丙丁酚治疗非增殖性糖尿病视网膜病变疗效显著,且并发症较少。Objective: To observe the clinical efficacy of probucol for nonproliferative diabetic retinopathy (NPDR). Methods: 68 patients with nonproliferative diabetic retinopathy (NPDR) were studied from Jan. 2012 to Aug. 2013. These patients were divided into four groups. Group A consisted of 17 patients receiving enhanced therapy and probucol;Group B consisted of 17 patients receiving enhanced therapy;Group C consisted of 17 patients receiving regular therapy and probucol;Group D consisted of 17 patients receiving regular therapy. Group A and Group C were given probucol of 0.375 g twice per day. All patients were followed up for average 11.58 ±0.17 months. The changes of best corrected visual acuity, fundus, total cholesterol (TC), low density lipoprotein- cholesterol (LDL-C) before therapy and one year after therapy were observed. Results: 1) The fundi of Group A and Group C were significantly improved (P 0.05);but the difference between the fundi of Group B and of Group D was not statistically significant (P >0.05). 2) The best corrected visual acuity of Group A and Group C was improved significantly (P 0.05);but the best corrected visual acuity of Group B and Group D did not change significantly (P >0.05). 3) The TC and LDLC level of Group A and Group C decreased significantly (P 0.05);There was no significant difference between the TC and LDLC level of Group A and of Group C (P >0.05). Conclusion: The efficacy of probucol for nonproliferative diabetic retinopathy is significant with less complications.

关 键 词：丙丁酚 非增殖性糖尿病视网膜病变 最佳矫正视力 眼底 

分 类 号：R5[医药卫生—内科学]